Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI

被引:10
作者
Solloway, Stephen [1 ,2 ,3 ]
Correia, Stephen [3 ]
Richardson, Sharon [4 ]
机构
[1] Butler Hosp, Dept Neurol, Memory & Aging Program, Providence, RI 02906 USA
[2] Brown Med Sch, Dept Clin Neurosci, Providence, RI 02912 USA
[3] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA
[4] Eisai Inc, Teaneck, NJ USA
关键词
mild cognitive impairment; clinical trials; treatment; donepezil; cholinesterase inhibitors;
D O I
10.1017/S1041610207005650
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: This paper reviews the key lessons learned from the first published short-term, placebo-controlled trial of a cholinesterase inhibitor for treatment of mild cognitive impairment (MCI). Methods: The study was a 24-week placebo-controlled trial designed to evaluate the efficacy and safety of donepezil HCl (donepezil) in the treatment of cognitive impairment in subjects with MCI. Primary outcome measures were the NYU Paragraphs Test and the ADCS Clinicians Global-Impression of Change in the intent-to-treat last-observation-carried-forward group. Results: There was no benefit of donepezil treatment on primary outcome measures (NYU Paragraphs and ADCS CGI-C) in the ITT-LOCF group but positive findings were seen on NYU Paragraphs in the fully evaluable group and in certain secondary outcome measures across both groups. Conclusions: The results highlight the need for the use of primary cognitive and functional measures that are reliable and sensitive to change in patients with MCI. Measures of episodic memory, psychomotor speed and complex attention were most sensitive in this study. Functional rating scales are needed that measure change in individual subjects' key areas of functional deficit, which typically involve executive aspects of instrumental ADLs. Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 12 条
[1]  
FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198
[2]   Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials [J].
Grundman, M ;
Petersen, RC ;
Ferris, SH ;
Thomas, RG ;
Aisen, PS ;
Bennett, DA ;
Foster, NL ;
Jack, CR ;
Galasko, DR ;
Doody, R ;
Kaye, J ;
Sano, M ;
Mohs, R ;
Gauthier, S ;
Kim, HT ;
Jin, S ;
Schultz, AN ;
Schafer, K ;
Mulnard, R ;
van Dyck, CH ;
Mintzer, J ;
Zamrini, EY ;
Cahn-Weiner, D ;
Thal, LJ .
ARCHIVES OF NEUROLOGY, 2004, 61 (01) :59-66
[3]   Neuropsychological prediction of decline to dementia in nondemented elderly [J].
Kluger, A ;
Ferris, SH ;
Golomb, J ;
Mittelman, MS ;
Reisberg, B .
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 1999, 12 (04) :168-179
[4]  
MOHS RC, 1988, PSYCHOPHARMACOL BULL, V24, P627
[5]  
Mohs RC, 1997, ALZ DIS ASSOC DIS, V11, pS13
[6]   THE CLINICAL DEMENTIA RATING (CDR) - CURRENT VERSION AND SCORING RULES [J].
MORRIS, JC .
NEUROLOGY, 1993, 43 (11) :2412-2414
[7]   Donepezil and vitamin E as treatments for mild cognitive impairment [J].
Petersen, R ;
Grundman, M ;
Thomas, R ;
Thal, L .
NEUROBIOLOGY OF AGING, 2004, 25 :S20-S20
[8]   Mild cognitive impairment - Clinical characterization and outcome [J].
Petersen, RC ;
Smith, GE ;
Waring, SC ;
Ivnik, RJ ;
Tangalos, EG ;
Kokmen, E .
ARCHIVES OF NEUROLOGY, 1999, 56 (03) :303-308
[9]   Efficacy of donepezil in mild cognitive impairment - A randomized placebo-controlled trial [J].
Salloway, S ;
Ferris, S ;
Kluger, A ;
Goldman, R ;
Griesing, T ;
Kumar, D ;
Richardson, S .
NEUROLOGY, 2004, 63 (04) :651-657
[10]  
Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22